I’ve owned Bristol-Myers Squibb (BMY) through two CEO changes, one near-catastrophic acquisition, and more patent cliff panic attacks than I care to count. The dividend alone has paid for my annual fishing trip to Alaska three times over. So when the street spent the better part of two years treating BMY like a condemned man, […]
Tag Archives: (BMY)
Mad Hedge Biotech and Healthcare Letter February 24, 2026 Fiat Lux Featured Trade: (THE CLIFF HANGER) (BMY), (PFE)
Mad Hedge Biotech and Healthcare Letter December 30, 2025 Fiat Lux Featured Trade: (BIOTECH’S WATERLOO: THE STOCKS THAT CONQUERED AND THE ONES THAT DIDN’T) (IDXX), (CAH), (HCA), (COR), (MCK), (GILD), (JNJ), (LLY), (ISRG), (WBA), (MRK), (BMY), (MRNA), (BIIB), (ILMN)
Napoleon once said, “In victory, you deserve champagne. In defeat, you need it.” Healthcare investors popped both in 2025. While the sector at large looked like a casualty of macro shrapnel, a few names marched through the battlefield with earnings like artillery fire – and stock prices to match. The top-line view was grim: the […]
Mad Hedge Biotech and Healthcare Letter December 23, 2025 Fiat Lux Featured Trade: (CLIMBING THE CLIFF IN REVERSE) (REGN), (AMGN), (MRK), (BMY), (NVO), (LLY)
A few months ago, I found myself sipping flat champagne on a Gulfstream out of Aspen, locked in one of those altitude-fueled biotech postmortems. On my left: a hedge fund manager freshly out of his biotech positions after a bruising year. On my right: a dermatologist who moonlights as a GLP‑1 evangelist. Regeneron (REGN) came […]
Mad Hedge Biotech and Healthcare Letter November 25, 2025 Fiat Lux Featured Trade: (THE COMEBACK CAT WITH MORE THAN NINE LIVES) (PFE), (NVO), (BMY), (JNJ)
The market has the memory of a goldfish and the gratitude of a cat. Pfizer (PFE) saved the world, then watched its stock get tossed out like last week’s leftovers. But the story isn’t over. Not when the company is quietly stitching together a pipeline, beating estimates the analysts didn’t think it could beat, and […]
Mad Hedge Biotech and Healthcare Letter September 30, 2025 Fiat Lux Featured Trade: (WHY ISN’T ANYONE WATCHING THIS BIOTECH DO EVERYTHING RIGHT?) (REGN), (SNY), (AMGN), (RHHBY), (MRK), (BMY), (NVO), (FUJIY)
Here’s a test of whether your analyst does actual homework or just regurgitates press releases: ask them about Regeneron’s (REGN) development balance with Sanofi (SNY). I can almost guarantee the blank stares that usually follow. That obscure line item buried in the 10-Q filing dropped $253 million last quarter to $1.2 billion, which means Regeneron’s […]